


# Disclosures None

# Outline

- Definition of tremor
- Phenomenology of tremor
- Several important tremor types
- Useful resources






https://tremorjournal.org/



#### What is tremor?

An involuntary, rhythmic, oscillatory movement of a body part.




Bhatia, et al (2018).




## Phenomenology of Tremor

- Often described based on activation state:
  - Rest tremor
  - Action tremor
- Other features:
  - Frequency (Hz)
  - Body part affected
  - Occurrence of associated medical conditions
  - Brain region from which the tremor arises (more rarely used)



#### Activation conditions and frequencies








# Essential Tremor: a common action tremor

- Prominent kinetic tremor, usually slightly asymmetric
- May have a family history of a similar tremor
- − ~50% have an intention tremor component
- Often have a postural tremor, generally out of phase in each arm
- Tremor at rest occurs in up to 35% of cases, but as a late feature
- Tremor worsens over time, often spreading





- An action tremor in the hands of virtually everyone
- A high frequency, lower amplitude postural and kinetic tremor
- No intention tremor and no neck tremor (neck tremor is always pathologic)
- Worsens with anxiety, hyperthyroidism, caffeine, lack of sleep, etc.





## Drug-induced Action Tremor

- Medications can produce or exacerbate action tremors
- Lithium
- Immunosuppressants (cyclosporine)
- Hormones (levothyroxine)
- Antiseizure medications (valproic acid)
- Methylxanthines (theophylline)
- Arsenic, manganese, and mercury toxicity
- Should NOT have head tremor
- Should NOT progressively worsen with stable medication dose



# Rest (aka resting) tremor-Parkinson's disease

- Generally asymmetric, affecting one side of the body to start
- May also affect the jaw (typically while mouth closed/relaxed)



#### Drug-induced rest tremor

- Dopamine blocking medications (anti-psychotics, metoclopramide, prochlorperazine) and dopamine-depleting agents (tetrabenazine, reserpine)
- Rarely:
  - Valproic acid
  - Lithium
- Tremor begins after exposure
- Typically improves and ceases within a year after stopping the offending drug
- Generally, not progressive



# Drugs of abuse and parkinsonism

- MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine)
- Methamphetamine
- ? Cocaine



#### **Functional Tremor**

- Often has an abrupt beginning with maximal tremor at onset
- May fluctuate with periods of remission
- The exam is key!
  - Distractibility
  - Suggestibility
  - Variability
  - Entrainment

https://youtu.be/MC5uOFZN83Q



#### Conclusions

- Tremor is a rhythmic, oscillatory movement
- Tremors are classified as action or rest tremors
  - Kinetic and postural tremors are the 2 main types of action tremors
- The major conditions with action-predominant tremors:
  - Essential tremor, enhanced physiologic tremor, and drug-induced tremor
- The major conditions with rest-predominant tremors:
  - Parkinson's disease and drug-induced tremor

## Tremor Resources

- Continuum Article on Tremor
- Consensus Statement on the Classification of Tremors
  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530552/
- Yale Movement Modules
  - http://movementmodules.yale.edu/



#### References

- Bhatia, et al. (2018). Consensus Statement on the classification of tremors from the task force on tremor of the International Parkinson and Movement Disorder Society. *Movement disorders*. 33(1), 75–87. https://doi.org/10.1002/mds.27121
- Elble, R. and Deuschl, G. (2011), Milestones in tremor research. Mov. Disord., 26: 1096-1105. https://doi.org/10.1002/mds.23579
- Gitlin M. (2016). Lithium side effects and toxicity: prevalence and management strategies. *International journal of bipolar disorders*, 4(1), 27. https://doi.org/10.1186/s40345-016-0068-y
- Louis, E. D. (2019). Tremor. CONTINUUM: Lifelong Learning in Neurology, 25(4), 959–975.
  https://doi.org/10.1212/con.0000000000000748
- Mursaleen, L. R., & Stamford, J. A. (2016). Drugs of abuse and parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 209–217. https://doi.org/10.1016/j.pnpbp.2015.03.013